United Kingdom-based AstraZeneca has failed to meet its primary endpoint in the Galathea phase III trial of its respiratory drug Fasenra (benralizumab), it was reported yesterday.
The study has failed to achieve statistically-significant reduction in exacerbations in patients with chronic obstructive pulmonary disease. The company is continuing the Terranova trial, which is also a second phase III trial of Fasenra. The results from the trial are likely to be revealed by the end of this quarter.
Galathea and Terranova are randomised, double-blinded, 56-week placebo-controlled and multi-centre trials, intended to assess the safety and efficacy of Fasenra as an add-on to dual or triple inhaled therapy compared with placebo in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of exacerbations across a range of baseline blood eosinophils. The safety and tolerability findings in the Galathea study are in line with the earlier trials conducted with Fasenra.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients